Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Viracta Therapeutics ( (VIRX) ).
On February 3, 2025, Viracta Therapeutics’ Board of Directors approved a plan to terminate its employees and wind down operations, effective February 5, 2025. The company anticipates incurring workforce reduction costs of around $0.1 million and is exploring strategic alternatives for its development programs. Concurrently, all board members resigned, and key officers departed from their roles, with Craig R. Jalbert appointed as the new CEO and sole board member to oversee the wind-down process.
More about Viracta Therapeutics
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company specializing in the treatment and prevention of virus-associated cancers globally.
YTD Price Performance: -80.56%
Average Trading Volume: 2,754,897
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.4M
See more insights into VIRX stock on TipRanks’ Stock Analysis page.
